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Abstract
Objective. The aim of the present study was to explore the long-term outcome and clinical characteristics
of adult patients with juvenile onset in the EULAR Scleroderma Trials and Research (EUSTAR) cohort and
compare them with adult patients with onset between 20 and 40 years of age.
Methods. From the EUSTAR SSc cohort two patient groups were analysed: patients with juvenile SSc
(jSSc) who are adults at present, and patients diagnosed between the age of 20 and 40 years (aSSc).
Demographic data of the patients, organ involvement and outcome of the disease were examined using
the Minimal Essential Data Set database system.
Results. From 5000 patients in the EUSTAR cohort, 60 patients (1.2%) with jSSc and 910 patients (18%) with
aSSc were selected according the inclusion criteria. In the jSSc group, the mean age of disease onset was
12.4 years (range 215.9 years), and in the aSSc group, the mean age was 32 years (range 2040 years).
Disease subsets were similar. The antibody profile was also comparable except for ACAs, which were positive
in 5% of the jSSc group and 26.9% of the aSSc group (P< 0.005). Organ involvement (lung, kidney, joint,
muscle and heart) was similar in the two groups of patients at the time of the last follow-up.
Conclusion. The subset distribution in the jSSc and aSSc cohorts was found to be similar. Only the
frequency of ACAs was significantly lower in the jSSc, which supports the hypothesis that the SSc pa-
tients with paediatric onset in the adult cohort may represent a distinct subgroup of the complete cohort
of paediatric patients.
Key words: juvenile scleroderma, juvenile systemic sclerosis, systemic sclerosis, outcome, prognosis, organ
involvement, diffuse subtype, limited subtype, antibody profile, EUSTAR.
Introduction
Juvenile SSc (jSSc) is a rare disease in childhood, with an
estimated incidence of 0.05 per 100 000 [1] and a preva-
lence of 1 in 1 000 000. It has been hypothesized that
10% of all SSc patients develop the disease before the
age of 16 years but nothing is known about whether pu-
berty has any influence on the incidence. One of the major
problems that has to be discussed frequently with a jSSc
patient and his/her family is the long-term outcome of the
disease. Obviously survival of the affected patient is a
pivotal problem, and it is known that the 5-year survival
of jSSc patients ranges between 95% [2] and 93% [3]
according to the two existing multinational retrospective
paediatric surveys. Approximately 90% of the patients in
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these paediatric cohorts are affected by the diffuse form
of SSc; this appears to be a different disease pattern
compared with the adult cohorts. However, at present,
only few data are available addressing the long-term out-
come of these patients from youth to adulthood. Therefore
the purpose of our study was to explore the long-term
outcome and clinical characteristics of adult patients with
juvenile onset SSc (jSSc) and compare them with young
adult-onset SSc (aSSc) patients from the European
League Against Rheumatism (EULAR) Scleroderma Trials
and Research (EUSTAR) [4].
Methods
Up to April 2006, 5000 patients were registered in the
EUSTAR database [4]. Patients were classified according
to the ACR preliminary classification criteria [5], and the
subset was defined according to the LeRoy criteria [6]. In
this database, data of the patients were collected in
the Minimal Essential Data Set (MEDS) [MEDS parameters
and video coaching material are also available at the
EUSTAR website (http://www.eustar.org)] [4], which has
been established by a consensus process of the
EUSTAR members. It covers demographic aspects, dis-
ease duration, organ involvement and laboratory data.
Patient data were extracted from this database,
selecting subjects with the first non-Raynaud presentation
before the age of 16 years. This group was split into early-
onset jSSc, onset of first non-Raynaud symptoms be-
fore the age of 10 years (prepubertal) and late-onset (pu-
bertal) jSSc with age of onset after the age of 10 years.
(The mean age of girls starting puberty reaching Tanner
stage 2 is between 9.5 and 9.7 years [7], and for boys with
systemic JRA it is 10.8 years [8]. This explains the cut-off
at the age of 10 years.) We chose as comparison patients
who had the first non-Raynaud presentation between
20 and 40 years of age. Demographic data, organ involve-
ment, laboratory data and outcome of these patients were
evaluated according to the guidelines of the MEDS
database [4]. A comparison with previous published
series was performed using the Student’s t-test for stat-
istical analysis with the significance set at P< 0.05.
Results
Sixty patients (1.2% of the whole EUSTAR cohort) with
jSSc (juvenile onset, age of onset before the age of
16 years) were identified, 55 females and 5 males (fe-
male : male = 11 : 1). Interestingly, when we divided
patients by age of onset before or after the age of
10 years, the male/female ratio was significantly different
between the two groups (P= 0.012). It was 1 : 2.75 before
10 years of age compared with 1 : 21.5 between 10 and 16
years of age (Table 1). The disease subset distribution also
differed: patients with prepubertal onset had an increased
proportion of diffuse subset patients: 60% compared with
35% (P= 0.192). None of the prepubertal patients had
ACAs (P= 0.673). The modified Rodnan skin score was sig-
nificantly higher in patients with prepubertal onset: 17.5
compared with 10.7 in those with onset after the age of
10 but< 16 years (P= 0.027). Interestingly, patients with
prepubertal onset had less gastrointestinal involvement
(P> 0.05). The proportions of patients with pulmonary fi-
brosis were similar. The mean age at disease onset in the
whole jSSc group was 12.4 years (range 215.9) with a
mean disease duration of 17.6 years (1.854.8).
The aSSc (adult-onset) group, age of onset between
20 and 40 years, consisted of 910 patients (representing
18% of the EUSTAR cohort). In all, 810 of the patients
were females and 100 were males (male : female = 1 :
8.1). Mean age at disease onset was 32 years (range
2040). The mean disease duration was 12.5 years
(247.5). The disease was active according to EUSTAR
activity score [4] at the time of last follow-up in 26.6% of
jSSc patients and 24.8% of aSSc patients. In jSSc, 59
(98%) of the 60 patients were alive at the last follow-up
and 1 was lost to follow-up. In aSSc, 898 (99%) patients
were alive at the last follow-up, 7 died and 5 were lost to
follow-up (Table 2). The distribution of the disease subsets
was statistically not different. In the whole jSSc group,
42% of patients had a diffuse subset, 49% had a limited
subset and 9% had an overlap syndrome. In aSSc, 38.2%
of patients had a diffuse subset, 53.1% had a limited
subset and 8.7% had an overlap syndrome (Table 2).
The antibody profile was also comparable with regard
to the presence of ANA: 90% in the jSSc group and 92.8%
in the aSSc group. Anti-Scl-70 was positive in 40% of the
jSSc and 40.7% of aSSc patients. There was a significant
difference in the frequency of ACAs, 5% in the jSSc group
and 27.8% in the aSSc group (P< 0.005) (Table 2). Organ
involvement showed a similar pattern in the two groups of
patients at the time of the last follow-up (Table 3), with no
significant difference in any of the evaluated and affected
organs.
Discussion
Our study shows interesting differences in prepubertal-
and pubertal-onset patients with adult jSSc. Prepubertal
children have a significantly increased proportion of male
patients and significantly higher mean modified Rodnan
skin score (Table 1). The main difference between jSSc
and aSSc patients is the significantly decreased fre-
quency of ACAs in the jSSc patients. Scalapino et al. [9]
and Foeldvari et al. [13] found a similar decreased fre-
quency of ACAs in a similar study looking at paediatric-
onset patients in adulthood (Table 4). It could be hypothe-
sized that this reflects the predominance of the diffuse
subset in childhood, persisting only in the antibody profile
but not in the amount of skin involvement. As adult pa-
tients were characterized by the physician currently treat-
ing them, they could have had diffuse-onset disease in
childhood. In our jSSc cohort, the number of patients
with anti-Scl 70 was 40% compared with 33% in the
Royal Free cohort [12] and 23% in the Pittsburgh cohort
[9]. Despite the difference in antibody expression, we
could not demonstrate significant differences regarding
organ involvement between the groups in the EUSTAR
cohort. These results are in contrast to the data from
Scalapino et al. [9], in which the study groups were
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defined as onset of disease before the age of 16 years
and young adults with onset of disease between 16 and
40 years of age. They found significant differences in
organ involvement: the mean modified skin score at pres-
entation and the frequency of renal crisis were lower in the
juvenile-onset group, whereas skeletal muscle involve-
ment was twice as frequent in the juvenile-onset group
[9]. Unlike our study, the Pittsburgh survey also found a
significantly higher proportion of jSSc patients with over-
lap syndrome and this observation was confirmed in the
population of the Royal Free cohort [13].
Although disease duration at last follow-up was similar
in the Pittsburgh survey and our cohort, the survival of
our paediatric patients was not different from the adult-
onset patients; survival was worse in the paediatric
group in the Pittsburgh cohort [9]. The survival rate in
the Royal Free cohort at 5, 10, 15 and 20 years was
100, 98, 95 and 82%, respectively, comparable to that
of the EUSTAR cohort. One of the explanations for these
differences could be that the recruitment of patients in
the Pittsburgh cohort started in 1960, whereas in the
EUSTAR cohort and Royal Free cohort the patients
were followed and treated more recently. During this
time period the mortality of SSc changed significantly
[10], with a better outcome in the current era. Another
explanation is the difference in ethnic background of the
study populations. This is pointed out in a publication
from the Pittsburgh group when comparing the
Pittsburgh cohort with a French cohort, where the pa-
tients are predominantly Caucasian, with a less severe
disease course in the latter [11]. The Caucasian ethnic
pattern is also prevalent in the EUSTAR cohort.
The subset distribution in favour of dSSc is unique to
this juvenile SSc cohort [3], whereas the adult juvenile-
onset patients in all three cohorts have a subset distribu-
tion similar to that of adult-onset SSc patients, but the
Royal Free cohort and the Pittsburgh cohort consist of a
significant proportion of patients (37%) with overlap fea-
tures [13]. The adult prepubertal-onset patients show a
similar increased diffuse subset dominance. This change
in the subset distribution over time from paediatric to adult
jSSc patients is presumably the result of a survival bias of
the limited subset or of decreased skin involvement of
diffuse patients over time.
It is noteworthy that the antibody profile is similar in the
juvenile-onset cohorts in adulthood (Table 4), with a low
number of patients with ACAs, a feature that appears to
be predominant in jSSc patients. In the publication from
TABLE 1 Characteristics of patients with first non-Raynaud symptoms before the age of 10 and between 10 and
16 years of age
Characteristics of patients and organ involvement
First non-Raynaud
<10 years of age
First non-Raynaud
>10 years of age P
Number of patients 15 45 
Age at disease onset, mean (range), years 7.57 (210) 13.79 (1016) 
Sex (female/male) 4 (26)/11 1 (2.2)/44 0.012
Disease duration, years 17.8 17.15 
Alive 15 45 
ACR criteria fulfilled 13/15 40/45 
Disease subseta
Diffuse 9 (60)/15 15 (36)/42 0.192
Limited 5 (33)/15 23 (55)/42 0.300
ANA positive 12 (80)/15 42 (93)/45 0.159
ACA positive 0 (0)/15 3 (6.8)/44 0.673
Anti-Scl 70 antibody positive 6 (40)/15 18 (40)/45 1.000
Raynaud’s 14 (93)/15 43 (95)/45 1.000
Digital ulceration 4 (28)/14 17 (38)/45 0.281
Modified Rodnan skin score, median (range) 16 (236) 7 (042) 0.027
Active at last follow-up 3 (20)/15 14 (31)/45 
Proteinuria 1 (6.6)/15 1 (2)/44 0.585
Renal hypertension 1 (6.6)/15 4 (9)/45 1.000
Renal crisis 0 (0)/15 0 (0)/45 
Arthritis 1 (6.6)/15 5 (11)/45 1.000
Contractures 6 (40)/15 12 (27)/45 0.347
Muscle weakness 2 (13)/15 10 (10)/45 0.712
Gastrointestinal involvement
Oesophagus 6 (40)/15 30 (66)/45 0.126
Stomach 1 (6.6)/15 9 (20)/45 0.426
Colon 1 (6.6)/15 8 (18)/44 0.568
Pulmonary fibrosis 3 (20)/15 11 (24)/45 1.000
Pulmonary hypertension 2 (13)/15 6 (14)/44 1.000
Data are represented as n (%)/total n, unless otherwise mentioned. aSome data missing, therefore not 100%.
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the Pittsburgh cohort, the assessment and comparison
with the EUSTAR cohort for each organ system is difficult
due to lack of recorded data. However, hypertension ap-
pears to occur more often in the adult juvenile cohort and
synovitis occurs more often in the paediatric-age juvenile
cohort.
The strengths of our data consist in the large number
of cases collected and examined by experts in the field
using a pre-designed survey tool. A weakness is that it is a
cross-sectional survey at many centres without standar-
dized assessment of organ involvement and serology.
Our study presents one of the largest adult jSSc patient
cohorts compared with an adult cohort of aSSc patients.
Interestingly, the antibody profile with the low frequency of
ACAs persists into adulthood. The subset pattern of the
jSSc cohort in adulthood resembles that of adult-onset
patients in all other ways. Interestingly, we could even
show some differences in patients with disease onset
before and after 10 years of age; especially interesting is
the higher rate of males aged <10 years. The survival bias
is presumably related to the higher rate of death in the
juvenile-onset diffuse SSc patients between the paediatric
age and the time of observation in the EUSTAR cohort or
to the decreasing skin involvement over time. To gain
knowledge regarding the disease between the paediatric
and adult cohorts, the prospective Juvenile Systemic
Scleroderma Inception Cohort Project (ww.juvenile-
scleroderma.com) could help, where new-onset jSSc
TABLE 2 Characteristics of the adult jSSc and aSSc patients from the EUSTAR cohort
Characteristics of patients and
organ involvement
Adult jSSc (age of diagnosis
<16 years of age)
aSSc (age at diagnosis
between 20 and 40 years of age) P
Number of patients 60 910 
Sex (female/male) 55 (92)/5 806 (89)/100 0.744
Age at disease onset, mean (range), years 12.4 (215.9) 32 (2040) 
Disease duration, mean (range), years 17.6 (1.854.8) 12.5 (247.5) 
Alive, n 59 (1 lost to follow-up) 898 (5 lost to follow-up) 
Disease subset
Diffuse 24 (42)/57 344 (38.2)/900 0.055
Limited 28 (49)/57 478 (53.1)/900 0.056
Overlap 5 (9)/57 78 (8.7)/900 0.071
Modified Rodnan skin score, median (range) 9 (042) 9 (043) 0.697
ANA positive 54 (90)/60 838 (92.8)/903 0.642
Anti-Scl 70 antibody positive 24 (40)/60 361 (40.7)/886 0.639
ACA positive 3 (5)/59 245 (27.8)/880 0.000
Active disease at last follow-up, % 26.6 24.8 
Data are represented as n (%)/total n, unless otherwise mentioned.
TABLE 3 Clinical characteristics of the juvenile onset and young adult-onset SSc EUSTAR cohort
Organ involvement
Adult jSSc cohort (age at onset
<16 years of age) (n= 60)
aSSC cohort (age at onset between
20 and 40 years of age) (n= 910) P
RP 95 95.1 1.000
Digital ulcers 35 41.3 0.208
Pulmonary hypertension 13.3 14.4 1.000
Pulmonary fibrosis 23.3 36 0.058
Hypertension 8.3 11 0.727
Renal crisis 0 2 0.707
Proteinuria 3.3 5.8 0.556
Oesophageal involvement 60 65.2 0.509
Gastric involvement 16.7 26.1 0.228
Intestinal involvement 15 22.4 0.210
Synovitis 10 15.4 0.558
Joint contractures 30 36.9 0.574
Muscle weakness 20 24.2 0.615
Tendon friction rub 8.3 12.2 0.574
Data are represented as percentages, unless otherwise mentioned.
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patients with a disease course of <18 months are fol-
lowed prospectively.
Rheumatology key messages
. The subset distribution of jSSc patients in adult-
hood and the aSSc cohort was similar.
. Only the frequency of ACAs was significantly lower
in jSSc patients than in adult-onset SSc patients.
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